Literature DB >> 7929810

Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1.

W G Haynes1, M F Hand, H A Johnstone, P L Padfield, D J Webb.   

Abstract

Endothelin-1 is a potent endothelium-derived vasoconstrictor peptide. Although circulating concentrations are not increased in essential hypertension, enhanced sensitivity to endothelin-1 has been observed in animal models of hypertension. We investigated dorsal hand vein responses to local infusion of endothelin-1 and norepinephrine in 12 patients with essential hypertension who had never received treatment and in 12 age and sex matched normotensive control subjects. The maximal venoconstriction and the geometric mean of the dose of norepinephrine that caused 50% of maximal venoconstriction were similar in hypertensive (mean +/- SE; 80 +/- 4%; 31 +/- 8 pmol/min) and normotensive subjects (87 +/- 5%, 22 +/- 9 pmol/min). In contrast, mean venoconstriction to endothelin-1 was significantly greater in hypertensive (49 +/- 5%) than in normotensive subjects (27 +/- 2%; P = 0.004). Sympathetically mediated venoconstriction elicited by deep breath was substantially potentiated by endothelin-1 in hypertensive (67 +/- 7% at 90 min) but not normotensive subjects (11 +/- 3% at 90 min; P = 0.001). Venoconstriction to endothelin-1 correlated positively with mean arterial pressure in the hypertensive subjects (r = 0.82; p = 0.001) but negatively in the normotensive subjects (r = -0.58; p = 0.047). Endothelin-1 may contribute to the reduction of venous compliance occurring in the early stages of essential hypertension and to the altered systemic hemodynamics in this condition.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929810      PMCID: PMC295255          DOI: 10.1172/JCI117470

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  47 in total

1.  The fourth Volhard lecture: cardiovascular structural adaptation; its role in the initiation and maintenance of primary hypertension.

Authors:  B Folkow
Journal:  Clin Sci Mol Med Suppl       Date:  1978-12

2.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells.

Authors:  M Yanagisawa; H Kurihara; S Kimura; Y Tomobe; M Kobayashi; Y Mitsui; Y Yazaki; K Goto; T Masaki
Journal:  Nature       Date:  1988-03-31       Impact factor: 49.962

3.  Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man.

Authors:  J G Collier; R E Lorge; B F Robinson
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

4.  Role of central blood volume in hyperkinetic borderline hypertension.

Authors:  C N Ellis; S Julius
Journal:  Br Heart J       Date:  1973-04

5.  Comparison of the reflex reactivity of skin and muscle veins in the human forearm.

Authors:  R Zelis; D T Mason
Journal:  J Clin Invest       Date:  1969-10       Impact factor: 14.808

6.  Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells.

Authors:  I Komuro; H Kurihara; T Sugiyama; M Yoshizumi; F Takaku; Y Yazaki
Journal:  FEBS Lett       Date:  1988-10-10       Impact factor: 4.124

7.  A new technique for recording compliance of human hand veins.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

8.  Rapid dextran infusion in essential hypertension.

Authors:  M E Safar; G M London; J A Levenson; A C Simon; N P Chau
Journal:  Hypertension       Date:  1979 Nov-Dec       Impact factor: 10.190

9.  Comparative changes in segmental vascular resistance in response to nerve stimulation and to norepinephrine.

Authors:  F M Abboud; J W Eckstein
Journal:  Circ Res       Date:  1966-03       Impact factor: 17.367

10.  Plasma endothelin following cardiac arrest: differences between survivors and non-survivors.

Authors:  W G Haynes; D W Hamer; C E Robertson; D J Webb
Journal:  Resuscitation       Date:  1994-03       Impact factor: 5.262

View more
  14 in total

1.  Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.

Authors:  N C Davidson; W J Coutie; D J Webb; A D Struthers
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 2.  Role of endothelin in the control of peripheral vascular tone in human hypertension.

Authors:  S Taddei; A Virdis; L Ghiadoni; I Sudano; A Magagna; A Salvetti
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

3.  Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men.

Authors:  Neeraj Dhaun; Fiona E Strachan; David E Newby; Neil R Johnston; Neville F Ford; Janis L Hammett; Maria Palmisano; David J Webb
Journal:  Br J Clin Pharmacol       Date:  2005-12       Impact factor: 4.335

Review 4.  Endothelial dysfunction and hypertension.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1997       Impact factor: 9.546

Review 5.  The clinical potential of endothelin receptor antagonists in cardiovascular medicine.

Authors:  C J Ferro; D J Webb
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 6.  Endothelin receptor antagonists and cardiovascular diseases of aging.

Authors:  M P Love; J J McMurray
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 7.  Endothelin in congestive heart failure.

Authors:  M P Love; J J McMurray
Journal:  Basic Res Cardiol       Date:  1996       Impact factor: 17.165

Review 8.  Endothelin in cardiovascular control: the role of endothelin antagonists.

Authors:  R R Wenzel; P Czyborra; T Lüscher; T Philipp
Journal:  Curr Hypertens Rep       Date:  1999 Feb-Mar       Impact factor: 5.369

Review 9.  Role of endothelin-1 in hypertension.

Authors:  Marc Iglarz; Ernesto L Schiffrin
Journal:  Curr Hypertens Rep       Date:  2003-04       Impact factor: 5.369

10.  An investigation into the direct and indirect venoconstrictor effects of endothelin-1 and big endothelin-1 in man.

Authors:  W G Haynes; S Moffat; D J Webb
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.